DraftUnitedHealthcarePolicy CS1OZIN.08

Rhinoplasty and Other Nasal Procedures (for Indiana Only)

State-specific UnitedHealthcare medical policy governing coverage criteria, definitions, coding, and evidence considerations for rhinoplasty and other nasal procedures for Indiana members and providers.

Policy Summary

PayerUnitedHealthcare

PolicyRhinoplasty and Other Nasal Procedures (for Indiana Only)

Policy CodePolicy CS1OZIN.08

Change TypeCode list and operational updates

Effective DateJun 1, 2025

Next Review Date

Key ActionWhen requesting prior authorization, document failed maximal medical therapy (≥6 weeks), baseline NOSE or rTNSS scores, photos showing valve collapse, and a clear surgical plan including graft needs.

SourceLink

POLICY UPDATE CHANGES

Applicable Codes Removed CPT code 30999

Added notation to indicate CPT code 30460, 30462, and 30465 are not managed for medical necessity review for the state of Indiana at this time

Removed notation indicating CPT code 30120 is not managed for medical necessity review for the state of Indiana at this time

Supporting Information Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information

state-specificpolicy applies to

lists >20applicable codes enumerated

multiplenot medically necessary items

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

5%AE rate (implants)

24 momax follow-up in Latera studies

Coverage Criteria and Evidence

Nasal valve procedures / repair of nasal vestibular stenosis or alar collapse — Medically necessary

Covered when ALL of the following are present:

Primary criteria: Other causes of nasal obstruction (e.g., rhinosinusitis, allergic rhinitis, vasomotor rhinitis, nasal polyposis, adenoid hypertrophy, nasopharyngeal masses) have been adequately treated with maximal therapy and nasal obstruction persists

Examples listed in policy

Symptom requirement: Prolonged/persistent obstructed nasal breathing due to internal and/or external nasal valve compromiseProlonged/persistent defined as failure after >=6 weeks medical therapy

See Definitions

Septal/turbinate state: Nasal septal deviation and turbinate hypertrophy either: have been previously surgically treated; or are not present; or are scheduled to be surgically treated at the same time as the nasal valve procedure

Per surgical plan

Objective/visual documentation: Photos clearly document dynamic collapse of the internal and/or external nasal valve or anatomic deformities narrowing the internal and/or external nasal valve consistent with the clinical exam

Photographic documentation required

Functional test: Documented subjective and audible improvement in nasal airflow during a modified Cottle maneuver

Required documentation element

Surgical plan: Surgeon clearly describes which valve(s) are involved (internal, external, or both), whether compromise is static or dynamic, and provides a clear surgical plan including the need for a cartilage graft

Plan must be plainly stated

Rhinophyma excision — Medically necessary

Covered when ALL of the following are present:

Primary indications: Prolonged, persistent obstructed nasal breathing due to rhinophyma; OR chronic infection or bleeding unresponsive to medical management due to rhinophyma

Rhinophyma must be primary cause

Documentation: Photos clearly document rhinophyma as the primary cause of an anatomic mechanical nasal airway obstruction or chronic infection and are consistent with the clinical exam

Photographic evidence required

Intent of procedure: Proposed procedure is designed to correct the anatomic mechanical nasal airway obstruction and relieve nasal obstruction by correcting the deformity or to address chronic infection

Procedure intent must be documented

Procedures considered unproven / not medically necessary

Unproven procedures: Nasal septal swell body (NSB) reduction; absorbable polylactic acid nasal cartilage support implants (e.g., Latera); posterior nasal nerve or sphenopalatine ganglion ablation (radiofrequency or cryoablation; e.g., RhinAer, ClariFix); radiofrequency treatment of nasal valves (e.g., VivAer)

Listed as unproven due to insufficient evidence of safety/efficacy

Study-derived effectiveness/response criteria

Clinical outcomes and trial-defined responder criteria observed in the literature

Responder criteria used in implant trials: Responder defined as at least one NOSE class improvement or >=20% reduction in NOSE score>=20% NOSE reduction

Used as the primary endpoint in Stolovitzky et al. RCT and reported in prospective series

NSB procedure primary endpoint: Primary endpoint in TCRF NSB study was improvement in NOSE score from baseline to 3 monthsclinically meaningful NOSE reduction reported (e.g., ~65% in Pritikin)

Pritikin reported durable improvements through planned follow-up

PNN / RhinAer / TCRF trial-like eligibility

Procedural treatment for chronic rhinitis (PNN neurolysis/ablation) was studied under the following inclusion-like criteria in key trials:

PNN procedural eligibility used in trials: All of the following: chronic rhinitis symptoms >= 6 months; inadequate response to medical management including intranasal steroids; baseline rTNSS often >=6 with moderate–severe rhinorrhea subscore (2–3) and congestion subscore (1–3)rTNSS >= 6

Derived from randomized and prospective trials (Stolovitzky, Takashima)

NSB / SBVR eligibility

Criteria used in septal body (NSB/SBVR) studies:

NSB/SBVR eligibility: All of the following: symptomatic nasal obstruction associated with septal body hypertrophy and inferior turbinate hypertrophy refractory to medical therapy; imaging or endoscopy–confirmed thickened septal body

Based on small prospective and randomized studies with limited follow-up

Coverage‑relevant evidence summaries

Evidence and guidance summarized in this segment support the following interpretations:

PNN/SPG ablation (ClariFix/RhinAer): Studies including RCT(s), observational studies, and ECRI/AAO‑HNS reviews find these procedures safe and likely to provide symptom relief for chronic rhinitis at 3 months to up to 2 years, but long‑term (>2 years) effectiveness and comparative effectiveness versus other treatments are uncertain.evidence limited

AAO‑HNS endorsed use for medically refractory chronic rhinitis based on reviewed studies

Temperature‑controlled RF (VivAer/TCRF) for nasal valve collapse: RCT(s) and multiple observational studies show clinically significant improvements in NOSE scores and high responder rates up to 2 years in many cohorts, but evidence quality ranges from very low to fair and comparative effectiveness versus functional rhinoplasty is not well established.evidence mixed

ECRI rated evidence very‑low quality and recommended head‑to‑head studies

This policy distinguishes procedures that are reconstructive and medically necessary from those that are cosmetic or unproven by requiring documentation that surgical treatment is intended to correct anatomic mechanical nasal airway obstruction. For nasal valve repair (including repair of nasal vestibular stenosis or alar collapse), coverage requires demonstration that other causes of obstruction have been treated, that the patient has prolonged/persistent obstructed nasal breathing due to internal and/or external valve compromise, objective/visual documentation (photos) of the anatomic problem or dynamic collapse, and functional improvement with a modified Cottle maneuver. The surgeon must describe which valve(s) are involved, whether the compromise is static or dynamic, and provide a clear surgical plan including need for cartilage graft. In contrast, procedures listed as unproven/not medically necessary (see list below) lack sufficient evidence of safety or efficacy and are treated separately for coverage decisions.

The evidence base for many newer nasal interventions is limited by low study quality, small sample sizes, industry sponsorship, and short follow-up. Systematic reviews and evolving-evidence reports (ECRI, Hayes) note the need for sham-controlled, double‑blind randomized trials with standardized protocols and longer-term follow-up to establish durability and comparative effectiveness versus established surgical options. Where randomized data exist (for example, limited RCT evidence for some devices), follow-up beyond three months and independent replication are often lacking.

Additional evidence gaps identified include a paucity of long‑term (>2 year) outcome data, limited head-to-head comparisons to functional rhinoplasty or other established treatments, heterogeneous outcome measures across studies, and frequent use of adjunctive procedures that confound interpretation. Systematic reviews of PNN/SPG ablation (cryotherapy and RF) report symptomatic improvements at short-term follow-up but call for more independent, high‑quality randomized and comparative trials to define relative benefit and durability.

The policy lists specific procedures considered unproven and not medically necessary due to insufficient evidence, but does not promulgate blanket administrative exclusions beyond that clinical determination. Limitations in the available literature — including uncontrolled designs, crossover of controls, and industry sponsorship — are highlighted as factors that may lead to noncoverage or require additional justification in individual cases.

This Medical Policy is provided for informational purposes and must be applied in the context of the member's federal, state, or contractual benefit plan. In the event of a conflict, the federal, state, or contractual requirements govern. Providers and reviewers should consult the applicable benefit plan and the current Prior Authorization and Notification List when making coverage determinations.

Procedures specifically identified in this policy as unproven or not medically necessary include: nasal septal swell body (NSB) reduction; absorbable polylactic acid nasal cartilage support implants (e.g., Latera); posterior nasal nerve or sphenopalatine ganglion ablation using radiofrequency or cryoablation (e.g., RhinAer, ClariFix); and radiofrequency treatment of nasal valves (e.g., VivAer).

Across device and procedure types the available evidence is commonly characterized as low or very‑low quality by independent reviewers (Hayes, ECRI). When evidence is limited, decisions should be individualized: coverage may be supported where high‑quality documentation meets the medically necessary criteria (e.g., clear photos, failed maximal medical therapy, objective functional testing), but procedures supported only by poor-quality, single-arm, or industry‑sponsored data generally require additional justification.

For some devices and modalities, long‑term effectiveness is insufficiently established. ECRI and systematic reviews report clinically significant short‑ to mid‑term effects for certain interventions but note that follow‑up beyond two years and comparative effectiveness data versus traditional surgical treatments are limited or absent. This insufficiency should be considered when evaluating requests for coverage.

Hayes assessments summarized in the literature reviews generally concluded only minimal support for some uses of the VivAer radiofrequency procedure based on the limited and low-quality body of evidence. Such assessments underscore the need for better‑designed trials and may inform denials or requests for supplemental documentation when clinical criteria are not clearly met.

Procedure and Product Codes

Applicable procedure codes (CPT/HCPCS)mixed

30117	Excision or destruction (e.g , laser) of intranasal lesion; internal approach.
30120	Excision or surgical planing of skin of nose for rhinophyma.
30400	Rhinoplasty, primary; lateral and alar cartilages andlor elevation of nasal tip.
30410	Rhinoplasty, primary; complete, external parts including pyramid, lateral and alar cartilages, andlor elevation of nasal tip bony.
30420	Rhinoplasty, primary; including major septal repair.
30430	Rhinoplasty, secondary; minor revision (small amount of nasal tip work).
30435	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies).
30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies).
30460	Rhinoplasty for nasal deformity secondary to congenital cleft lip andlor palate, including columellar lengthening; tip only.
30462	Rhinoplasty for nasal deformity secondary to congenital cleft lip andlor palate, including columellar lengthening; tip, septum; osteotomies.

1–10 of 18

1/2

Coding references absent in this sectionmixed

no CPT/HCPCS codes listed

Document section does not list specific procedure or billing codes for implants or NSB procedures.

Procedure codes (not specified)mixed

Not listed

Specific CPT/HCPCS codes for cryoablation, TCRF, coblation, or microdebrider procedures are not provided in this document excerpt.

FDA product codes mentionedmixed

LRC	FDA product code LRC (instrument; ENT, manual surgical) — device category referenced.
LYA	FDA product code LYA (intranasal septal devices) — device category referenced.

Previously listed/removed CPT codesCPTNot Covered

30999

CPT code removed from applicable codes list

CPT codes not managed for medical necessity review in IndianaCPT

30460	CPT noted as not managed for medical necessity review (Indiana)
30462	CPT noted as not managed for medical necessity review (Indiana)
30465	CPT noted as not managed for medical necessity review (Indiana)

inv-23: Conservative medical management duration

Conservative medical management durationAt least 6 weeks of medical therapy (e.g., nasal steroids, antihistamines, decongestants) with elimination of drug‑induced rhinitis prior to considering surgical repair

Context'Prolonged; Persistent Nasal Airway Obstruction' is defined as failure to respond to six weeks of medical management

Documentation implicationPrior adequate medical management should be recorded in clinical documentation for prior authorization and coverage decisions

inv-24: NOSE score responder definition (as used in trials)

NOSE responder definition (trial standard)

Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for procedures and devices when member benefits or state-specific prior authorization lists indicate management. Providers should refer to the UnitedHealthcare Community Plan of Indiana Prior Authorization and Notification lists to confirm current authorization requirements before scheduling services.

Check the most up-to-date Indiana prior authorization and notification lists prior to submission.
All nasal surgical claims may be subject to coding review; codes with an asterisk may not be managed for medical necessity review for Indiana at policy effective date.

Prior Authorization

Prior Authorization — Implants and NSB Procedures

Prior authorization is recommended for absorbable nasal implants (e.g., Latera) and for procedures or devices related to nasal septal swell body (NSB) reduction and other investigational nasal procedures. Authorization requests should include the device name, FDA clearance status if applicable, and detailed clinical rationale.

When implants are planned, include device model (eg, Latera) and manufacturer information.

Clinical Background

Mechanical nasal airway obstruction refers to trouble breathing through the nose due to bony or cartilaginous deformity. Nasal valve compromise (internal and/or external) can produce persistent obstructed nasal breathing despite medical therapy; surgical repair is intended to correct the anatomic impairment and restore nasal airflow when conservative management has failed.

Key Definitions and Device Terms

inv-49: Mechanical Nasal Airway Obstruction — definition

DefinitionMechanical nasal airway obstruction: trouble breathing through the nose due to a bony or cartilaginous deformity (not snoring)

Clinical relevanceIncludes internal and/or external nasal valve compromise that can produce persistent obstructed nasal breathing

AssessmentObjective documentation (photos, endoscopy) and functional testing (modified Cottle maneuver) support diagnosis

inv-50: Prolonged; Persistent Nasal Airway Obstruction — definition requiring >=6 weeks medical management

DefinitionProlonged/Persistent Nasal Airway Obstruction: nasal breathing difficulty that has not responded to ≥6 weeks of medical management (e.g., nasal steroids, antihistamines, decongestants); drug‑induced rhinitis must be excluded

Prior therapy requirement

Policy Revision History

2025-06-01codes_updatedLatest

Removed CPT 30999 from the policy's applicable codes list.

2025-06-01codes_annotation_added

Annotated CPT codes 30460, 30462, and 30465 as not managed for medical necessity review for the state of Indiana (providers directed to check current PA/Notification List).

2025-06-01codes_annotation_removed

Policy Summary

PayerUnitedHealthcare

PolicyRhinoplasty and Other Nasal Procedures (for Indiana Only)

Policy CodePolicy CS1OZIN.08

Change TypeCode list and operational updates

Effective DateJun 1, 2025

Next Review Date

SourceLink

On This Page

Several devices (VivAer, Latera, ClariFix, RhinAer) have FDA 510(k) clearances for specified indications; FDA clearance is informational and not a coverage determination.

FDA clearances cited in policy

Responder = at least one NOSE class improvement OR ≥20% reduction in NOSE score (used as primary responder definition in Latera trials)

Example applicationStolovitzky and San Nicolo studies used this definition to report responder rates at 3–12 months

Use in documentationReport baseline and follow‑up NOSE class/score and calculate percentage change to determine responder status

inv-25: rTNSS threshold used in trials — ≥ 6 (common eligibility requirement)

rTNSS eligibility thresholdReflective Total Nasal Symptom Score (rTNSS) ≥ 6 commonly used as an enrollment/eligibility requirement in PNN/RF trials

Symptom componentsTrials required moderate–severe rhinorrhea and mild–severe congestion subscores in addition to total rTNSS ≥6

Documentation implicationPrior authorization should include baseline rTNSS when PNN or RF procedures are requested

For NSB reduction or TCRF procedures (e.g., VivAer), supply documentation of prior conservative management and symptom severity measures.

Prior Authorization

Clinical Eligibility Confirmation for Authorization

Prior authorization submissions must confirm the member meets clinical eligibility criteria consistent with reconstructive/medical necessity indications. Authorization review will verify trial-like eligibility where applicable (for example, chronic rhinitis ≥ 6 months for PNN/SPG procedures and baseline severity thresholds for nasal valve interventions).

For PNN/SPG ablation/cryotherapy: chronic rhinitis ≥ 6 months and baseline rTNSS ≥ 6 with required subscore thresholds when indicated.
For nasal valve procedures (TCRF, implants): baseline NOSE score and classification (eg, severe/extreme) should be provided.
Document duration of symptoms and prior response to therapies.

Prior Authorization

Device Clearance and Authorization

Include device-specific FDA clearance or regulatory information in authorization requests where available. FDA clearance alone does not guarantee coverage; it is informational and coverage is determined by benefit, state, and contractual requirements.

VivAer Stylus (TCRF) — 510(k) clearance March 2020; indicate if device will be used.
Latera Absorbable Nasal Implant — 510(k) clearance June 23, 2016; include implant details.
ClariFix and RhinAer devices — include 510(k) clearance dates and intended use when applicable.

Denial Risk

Denial Risk — Unproven Procedures

Procedures or technologies identified as unproven (and listed in this policy) may be denied as not medically necessary. Use of these unproven technologies without strong supporting documentation risks denial.

Examples of not medically necessary / unproven: NSB reduction, absorbable polylactic acid nasal cartilage support implants (eg, Latera) when not meeting criteria, PNN/SPG ablation or other novel techniques when evidence or indication is insufficient, and radiofrequency treatments of nasal valves outside established indications.
Providers should not assume coverage for procedures listed as unproven; provide comparative rationale if requesting exception.

Denial Risk

Denial Risk — Evidence Limitations

Evidence limitations (short follow-up, low-quality or nonrandomized studies, small cohorts, lack of long-term comparative data, or study designs vulnerable to bias) noted in the literature may trigger denial of coverage when clinical benefit cannot be established for the member’s specific presentation.

Short follow-up (eg, three months) without durable outcomes beyond 12–24 months may be insufficient for coverage determination.
Studies that lack control groups, are single-arm, or have high risk of bias weaken the evidence base used in medical necessity decisions.
When evidence is low or very low quality for a procedure in the requested indication, provide robust individualized documentation to support medical necessity.

Note

Coverage Governing Requirements

Coverage decisions must reference and be consistent with federal, state, or contractual benefit requirements. In the event of a conflict between this policy and specific benefit plan terms or state requirements, the federal/state/contractual requirements govern.

Before determining coverage, confirm the member’s benefit plan, state mandates, and any applicable InterQual or third-party tool determinations.
For Indiana members, consult the UnitedHealthcare Community Plan of Indiana prior authorization and notification lists for code management and state-specific rules.

Documentation Required

Required Clinical Documentation Elements

Provide comprehensive clinical documentation with prior authorization and upon claim submission. Required elements include objective and patient-reported baseline measures, prior conservative therapy attempts and durations, and documentation addressing other causes of nasal obstruction.

Baseline and post-procedure patient-reported outcome measures (eg, NOSE scores, rTNSS) with dates and numeric values.
Description and objective documentation of anatomic valve dysfunction (eg, visible external/alar collapse with deep inspiration, lateral wall insufficiency).
Evidence that other causes (eg, rhinosinusitis, allergic rhinitis, nasal polyps, adenoid hypertrophy) were treated and remain refractory.
Documentation of prior adequate medical management (eg, at least six weeks of medical therapy including intranasal corticosteroids, antihistamines, decongestants) and failed surgical management where applicable.
List of prior treatments tried (medications, duration, response) and any prior nasal surgeries with dates and outcomes.

Documentation Required

Documentation and Reference Requirements

Use the member’s benefit plan, applicable state/federal requirements, and UnitedHealthcare tools (such as InterQual) to support coverage decisions. This policy is informational and does not replace plan-specific or regulatory requirement checks.

Reference InterQual criteria where indicated for rhinoplasty and related surgical services.
Verify code management status for Indiana (eg, CPT codes 30460, 30462, 30465 notation) on the current prior authorization list.
If additional documentation is requested, respond with the specific clinical measures, imaging, operative plans, and device details to avoid delays or denials.

Prior Authorization

Conservative Therapy Prerequisite

Conservative therapy is a prerequisite for many interventions. The policy requires evidence of adequate medical management (eg, a minimum of six weeks of medical therapy such as intranasal corticosteroids, antihistamines, and decongestants) and elimination of reversible causes (eg, medication-induced rhinitis) before considering procedural therapies.

Document duration and specifics of conservative therapies (agents, dosing, dates) and objective/subjective response.
For chronic rhinitis interventions, trials of intranasal steroids (typically at least four weeks) and other appropriate medical therapy must be documented prior to authorization requests for ablative or device procedures.

Prior Authorization

Conservative Therapy Prior to Intervention

Before implants or nasal structural procedures, document that conservative and less invasive options were attempted and failed. Authorization reviewers will expect evidence that the requested intervention is the next appropriate step in management.

For nasal valve interventions and implants, show prior medical therapy and, when relevant, prior surgical treatment of septal deviation or turbinate hypertrophy unless those conditions are absent or scheduled to be treated concurrently.
Include rationale if concurrent procedures (eg, septoplasty, turbinate reduction) are planned with implant placement.

Prior Authorization

Failure of Medical Therapy Required

Authorization and coverage typically require documentation of failure of medical therapy appropriate to the indication. For valve collapse and chronic rhinitis interventions, note failed trials of intranasal steroids and other guideline-directed medical management before procedural treatment is pursued.

For PNN/SPG or RF/cryo procedures for chronic rhinitis, document inadequate response to at least four weeks (or longer where specified) of intranasal steroid therapy and other relevant medications.
For nasal valve procedures, document that symptoms persisted despite medical therapy and that obstruction is functionally related to valve collapse.

Note

Provider Action — Unspecified Administrative Items

Provider action note: Certain specific operational or administrative items were not specified in this document segment. When in doubt about submission requirements or unique case circumstances, contact UnitedHealthcare prior authorization support for Indiana or the plan’s medical policy help desk.

If a submission requires elements not listed here, UnitedHealthcare may request additional clinical records, imaging, or operative planning details.
Use the payer contacts on the prior authorization list for clarification of state-specific rules.

Policy and trial populations require documentation of failed medical therapy before surgical intervention

Implication for prior authorizationClinical records should document duration and type of medical treatments tried and exclusion of rhinitis medicamentosa

inv-51: External Nasal Valve — anatomic definition

Anatomic definitionExternal nasal valve comprises the caudal septum, lower lateral cartilage, alar rim, and nostril sill

Functional roleThese structures contribute to external nasal valve function and can cause obstruction when compromised

EvaluationExamination and photographic documentation should identify which external valve components are involved

inv-52: Latera (bioabsorbable nasal implant) — device definition and context

Device descriptionLatera: an absorbable polylactic acid (PLLA‑PDLA) copolymer implant placed to support the lateral nasal wall for treatment of dynamic nasal valve collapse

Clinical contextPlaced with a delivery tool within the nasal wall to provide lateral cartilage support; studied in RCTs and prospective case series reporting NOSE and VAS outcomes through 12 months

Safety/outcomesSystematic reviews report improved QOL and lateral wall stabilization with pooled adverse event incidence ~5% (skin/mucosal reaction, infection, implant retrieval) in analyzed studies

inv-53: TCRF (temperature-controlled radiofrequency) — device definition

Technique/device classTemperature‑controlled radiofrequency (TCRF): device‑based procedure delivering controlled RF energy to submucosal tissue to reduce septal swell body or remodel internal nasal valve tissues

Examples and indicationsUsed for septal swell body (NSB) reduction and internal nasal valve remodeling (e.g., VivAer) to relieve nasal airway obstruction

Evidence contextRCTs and prospective studies report clinically significant NOSE score improvements; studies are limited by short follow‑up and mixed quality

inv-54: rTNSS — Reflective Total Nasal Symptom Score definition

DefinitionReflective Total Nasal Symptom Score (rTNSS): a validated patient‑reported instrument measuring nasal symptoms used as a primary outcome in chronic rhinitis trials

Parts and scoring (trial use)Trials report total rTNSS with thresholds (commonly ≥6) and analyze subscores such as rhinorrhea and congestion to assess eligibility and response

Use in trialsPNN/RhinAer and related RF trials used rTNSS for enrollment and primary efficacy endpoints

inv-55: NSB / SBVR — Nasal septal swell body reduction definition

DefinitionNasal septal swell body (NSB) / septal body volume reduction (SBVR): surgical or device‑based procedures (e.g., coblation, microdebrider‑assisted reduction, TCRF) to reduce hypertrophy of the septal swell body contributing to nasal obstruction

TechniquesIncludes coblation, microdebrider‑assisted reduction, and temperature‑controlled RF approaches evaluated in small prospective and randomized studies

Evidence and limitationsStudies show symptomatic improvement at short‑term follow‑up (3–12 months) but are limited by small sample sizes and lack of long‑term data

inv-56: VivAer Stylus / TCRF — device definition and FDA context

Device name and classVivAer Stylus / TCRF: a temperature‑controlled radiofrequency stylus cleared by FDA (510(k)) for coagulation/shrinkage of submucosal tissue in the internal nasal valve to treat nasal airway obstruction

IndicationIntended to shrink submucosal tissue (including cartilage) in the internal nasal valve area to improve nasal airflow

Evidence summaryRandomized and prospective studies report clinically significant NOSE improvements and responder rates up to 2 years, though evidence quality varies

inv-57: ClariFix — cryosurgical device definition (FDA 510(k))

Device descriptionClariFix: a cryosurgical device cleared by the FDA (510(k), Feb 14, 2017) intended for tissue destruction to treat chronic rhinitis

Intended useUsed to ablate posterior nasal nerve or mucosal targets to reduce rhinitis symptoms in adults with chronic rhinitis

Evidence noteStudies and systematic reviews report symptom relief up to two years in some cohorts, but long‑term comparative effectiveness remains uncertain

inv-58: Latera — absorbable nasal implant definition (FDA 510(k))

Device descriptionLatera: an FDA‑cleared (510(k), June 23, 2016) absorbable nasal implant composed of PLLA‑PDLA copolymer, indicated to support upper and lower lateral cartilage

Clinical contextPlaced to provide lateral wall support for dynamic nasal valve collapse and studied in RCTs and prospective series with NOSE/VAS outcomes

Safety/evidenceSystematic reviews report improved QOL and lateral wall stabilization with short‑term follow‑up; retrieval and minor adverse events reported in a minority of patients

inv-59: RhinAer — stylus for posterior nasal nerve regions (FDA 510(k))

Device descriptionRhinAer Stylus: an FDA‑cleared (510(k), July 29, 2022) Class II stylus indicated for destruction of soft tissue in the nasal airway, including posterior nasal nerve regions for chronic rhinitis

Indication and useIntended for PNN/SPG region treatment to reduce chronic rhinitis symptoms via temperature‑controlled RF neurolysis in trialed devices

Evidence contextUsed in randomized and prospective trials of PNN neurolysis showing symptom reduction (rTNSS) versus sham or baseline

inv-60: bioabsorbable implant (Latera) — referenced in multiple systematic reviews and trials

Role in literatureLatera bioabsorbable implant is referenced across multiple systematic reviews, prospective case series, and at least one randomized trial assessing effectiveness for dynamic nasal valve collapse

Study follow‑upKey studies report outcomes through 12 months and pooled analyses cite maximum reported follow‑up in some studies up to 24 months

Evidence limitationsSystematic reviews note need for larger randomized trials and longer follow‑up to confirm durability

inv-61: temperature-controlled radiofrequency — device-based therapy with cited RCT and prospective evidence

DescriptionTemperature‑controlled radiofrequency (TCRF) is a device‑based therapy delivering controlled RF energy to nasal tissues for nasal valve remodeling or septal swell body reduction

Evidence baseMultiple prospective studies and randomized controlled trials (including Silvers RCT and multicenter prospective studies) report clinically significant NOSE improvements and responder rates; follow‑up ranges from 3 months to up to 2 years

Clinical implicationTCRF therapies have FDA‑cleared devices (e.g., VivAer) and trial evidence supporting short‑to‑mid‑term benefit, but comparative effectiveness vs surgical rhinoplasty and long‑term durability remain uncertain

Removed prior notation that CPT code 30120 is not managed for medical necessity review for the state of Indiana.

2025-06-01evidence_update

Supporting Information: updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

The policy references updated supporting literature and clinical evidence, including systematic reviews, randomized trials, prospective case series, and device‑focused evidence assessments (ECRI, Hayes). Key cited sources include meta-analyses and RCTs of absorbable implants (Latera), randomized and prospective studies of temperature‑controlled radiofrequency devices (VivAer/TCRF), and trials and reviews of posterior nasal nerve ablation techniques (ClariFix, RhinAer); these references form the basis for the policy’s evidence summaries and the identified limitations in long‑term and comparative data.